VRTX Jan 2025 240.000 call
| Previous Close | 188.34 |
| Open | 188.34 |
| Bid | 173.70 |
| Ask | 183.00 |
| Strike | 240.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 188.34 - 188.34 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
Insider MonkeyVertex Pharmaceuticals Incorporated (VRTX): A Promising Feminist Stock To Buy?
We recently compiled a list of the 11 Best Feminist Stocks To Invest In. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other feminist stocks. With the passage of time, the role of women in the modern day workplace has slowly started to grow. […]
Business WireVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON, June 14, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved CRI
GuruFocus.comInsider Sale: EVP and CMO Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
On June 12, 2024, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 2,280 shares of the company.
